These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 20166795)

  • 1. Predictors of placebo response in randomized controlled trials of psychotropic drugs for children and adolescents with internalizing disorders.
    Cohen D; Consoli A; Bodeau N; Purper-Ouakil D; Deniau E; Guile JM; Donnelly C
    J Child Adolesc Psychopharmacol; 2010 Feb; 20(1):39-47. PubMed ID: 20166795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials.
    Bridge JA; Iyengar S; Salary CB; Barbe RP; Birmaher B; Pincus HA; Ren L; Brent DA
    JAMA; 2007 Apr; 297(15):1683-96. PubMed ID: 17440145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Are child and adolescent responses to placebo higher in major depression than in anxiety disorders? A systematic review of placebo-controlled trials.
    Cohen D; Deniau E; Maturana A; Tanguy ML; Bodeau N; Labelle R; Breton JJ; Guile JM
    PLoS One; 2008 Jul; 3(7):e2632. PubMed ID: 18612460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
    Griebel G; Beeské S; Stahl SM
    J Clin Psychiatry; 2012 Nov; 73(11):1403-11. PubMed ID: 23146246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting placebo response in adolescents with major depressive disorder: The Adolescent Placebo Impact Composite Score (APICS).
    Nakonezny PA; Mayes TL; Byerly MJ; Emslie GJ
    J Psychiatr Res; 2015 Sep; 68():346-53. PubMed ID: 26028546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Obsessive-compulsive disorder has a reduced placebo (and antidepressant) response compared to other anxiety disorders: A meta-analysis.
    Sugarman MA; Kirsch I; Huppert JD
    J Affect Disord; 2017 Aug; 218():217-226. PubMed ID: 28477500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications.
    Khin NA; Chen YF; Yang Y; Yang P; Laughren TP
    J Clin Psychiatry; 2011 Apr; 72(4):464-72. PubMed ID: 21527123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Which factors predict placebo response in anxiety disorders and major depression? An analysis of placebo-controlled studies of escitalopram.
    Stein DJ; Baldwin DS; Dolberg OT; Despiegel N; Bandelow B
    J Clin Psychiatry; 2006 Nov; 67(11):1741-6. PubMed ID: 17196054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative efficacy of antidepressants in preventing relapse in anxiety disorders - a meta-analysis.
    Donovan MR; Glue P; Kolluri S; Emir B
    J Affect Disord; 2010 Jun; 123(1-3):9-16. PubMed ID: 19616306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relapse prevention and residual symptoms: a closer analysis of placebo-controlled continuation studies with escitalopram in major depressive disorder, generalized anxiety disorder, social anxiety disorder, and obsessive-compulsive disorder.
    Bech P; Lönn SL; Overø KF
    J Clin Psychiatry; 2010 Feb; 71(2):121-9. PubMed ID: 19961809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Initial severity and antidepressant efficacy for anxiety disorders, obsessive-compulsive disorder, and posttraumatic stress disorder: An individual patient data meta-analysis.
    de Vries YA; Roest AM; Burgerhof JGM; de Jonge P
    Depress Anxiety; 2018 Jun; 35(6):515-522. PubMed ID: 29659102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics of placebo responders in pediatric clinical trials of attention-deficit/hyperactivity disorder.
    Newcorn JH; Sutton VK; Zhang S; Wilens T; Kratochvil C; Emslie GJ; D'souza DN; Schuh LM; Allen AJ
    J Am Acad Child Adolesc Psychiatry; 2009 Dec; 48(12):1165-72. PubMed ID: 19858759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pharmacologic treatment of anxiety disorders: a review of progress.
    Ravindran LN; Stein MB
    J Clin Psychiatry; 2010 Jul; 71(7):839-54. PubMed ID: 20667290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suicide rates in short-term randomized controlled trials of newer antidepressants.
    Hammad TA; Laughren TP; Racoosin JA
    J Clin Psychopharmacol; 2006 Apr; 26(2):203-7. PubMed ID: 16633153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Placebo response in randomized controlled trials of antidepressants for pediatric major depressive disorder.
    Bridge JA; Birmaher B; Iyengar S; Barbe RP; Brent DA
    Am J Psychiatry; 2009 Jan; 166(1):42-9. PubMed ID: 19047322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment benefit and the risk of suicidality in multicenter, randomized, controlled trials of sertraline in children and adolescents.
    March JS; Klee BJ; Kremer CM
    J Child Adolesc Psychopharmacol; 2006; 16(1-2):91-102. PubMed ID: 16553531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Double-blind, crossover trial of fluoxetine and placebo in children and adolescents with obsessive-compulsive disorder.
    Riddle MA; Scahill L; King RA; Hardin MT; Anderson GM; Ort SI; Smith JC; Leckman JF; Cohen DJ
    J Am Acad Child Adolesc Psychiatry; 1992 Nov; 31(6):1062-9. PubMed ID: 1429406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role and clinical implications of atypical antipsychotics in anxiety disorders, obsessive-compulsive disorder, trauma-related, and somatic symptom disorders: a systematized review.
    Albert U; Carmassi C; Cosci F; De Cori D; Di Nicola M; Ferrari S; Poloni N; Tarricone I; Fiorillo A
    Int Clin Psychopharmacol; 2016 Sep; 31(5):249-58. PubMed ID: 26974213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation between different levels of placebo response rate and clinical trial outcome in major depressive disorder: a meta-analysis.
    Iovieno N; Papakostas GI
    J Clin Psychiatry; 2012 Oct; 73(10):1300-6. PubMed ID: 23140647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.